3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Active not recruiting
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Liposarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
pembrolizumab
29
Carboplatin
27
Specimen Handling
21
durvalumab
20
Pemetrexed
18
Cisplatin
17
Paclitaxel
16
atezolizumab
15
Nivolumab
15
Magnetic Resonance Spectroscopy
15
osimertinib
11
Radiosurgery
11
Radiotherapy
10
Immunoglobulin G
10
Etoposide
10
Docetaxel
10
Disulfides
10
Radiation
9
Taxes
8
Gemcitabine
8
Biopsy
8
Blood Specimen Collection
7
Standard of Care
6
Practice Guidelines as Topic
6
Ipilimumab
6
Surveys and Questionnaires
5
Platinum
5
Bronchoscopy
5
Bevacizumab
5
Ramucirumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lung Neoplasms
×
zimberelimab
×
Clear all
NCT04736173
2026-06-01
ARC-10
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
169 enrolled
NCT05633667
2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2
Active not recruiting
192 enrolled